Complix is backed by a syndicate of experienced life sciences investors. Since its founding in 2008, Complix has raised over €27 million in equity financing (approximately US$30 million).
The most recent financing (series C round) in 2017 was co-led by Edmond de Rothschild Investment Partners (currently Andera Partners, France), Gimv (Belgium) LRM (Belgium) and Vesalius Biocapital (Luxembourg). Gemma Frisius Fund, LRD, Omnes Capital, TrustCapital, PMV, Baekeland Fund and management also participated in this round.
